Evidence map›Paper›PMID 24624282›Full record

ReviewJournal of thoracic disease2014

The medical and surgical treatment of drug-resistant tuberculosis.

Gregory L Calligaro, Loven Moodley, Greg Symons, Keertan Dheda

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of thoracic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. ProbResist: a database for drug-resistant probiotic bacteria.Database : the journal of biological databases and curation · 2022
    Article
  10. Treatment as prevention and other interventions to reduce transmission of multidrug-resistant tuberculosis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Medical Management of Drug-Resistant Tuberculosis.Tuberculosis and respiratory diseases · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gregory L Calligaro1 Lung Infection and Immunity Unit, University of Cape Town Lung Institute, Cape Town, South Africa ; 2 Division of Pulmonology, Groote Schuur Hospital, Cape Town, South Africa ; 3 Division of Cardiothoracic Surgery, Groote Schuur Hospital, Cape Town, South Africa ; 4 Centre for TB Drug Research and Innovation, University of Cape Town Lung Institute, Cape Town, South Africa.
Loven Moodley1 Lung Infection and Immunity Unit, University of Cape Town Lung Institute, Cape Town, South Africa ; 2 Division of Pulmonology, Groote Schuur Hospital, Cape Town, South Africa ; 3 Division of Cardiothoracic Surgery, Groote Schuur Hospital, Cape Town, South Africa ; 4 Centre for TB Drug Research and Innovation, University of Cape Town Lung Institute, Cape Town, South Africa.
Greg Symons1 Lung Infection and Immunity Unit, University of Cape Town Lung Institute, Cape Town, South Africa ; 2 Division of Pulmonology, Groote Schuur Hospital, Cape Town, South Africa ; 3 Division of Cardiothoracic Surgery, Groote Schuur Hospital, Cape Town, South Africa ; 4 Centre for TB Drug Research and Innovation, University of Cape Town Lung Institute, Cape Town, South Africa.
Keertan Dheda1 Lung Infection and Immunity Unit, University of Cape Town Lung Institute, Cape Town, South Africa ; 2 Division of Pulmonology, Groote Schuur Hospital, Cape Town, South Africa ; 3 Division of Cardiothoracic Surgery, Groote Schuur Hospital, Cape Town, South Africa ; 4 Centre for TB Drug Research and Innovation, University of Cape Town Lung Institute, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multi drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) are burgeoning global problems with high mortality which threaten to destabilise TB control programs in several parts of the world. Of alarming concern is the emergence, in large numbers, of patients with resistance beyond XDR-TB (totally drug-resistant TB; TDR-TB or extremely drug resistant TB; XXDR-TB). Given the burgeoning global phenomenon of MDR-TB, XDR-TB and TDR-TB, and increasing international migration and travel, healthcare workers, researchers, and policy makers in TB endemic and non-endemic countries should familiarise themselves with issues relevant to the management of these patients. Given the lack of novel TB drugs and limited access to existing drugs such as linezolid and bedaquiline in TB endemic countries, significant numbers of therapeutic failures are emerging from the ranks of those with XDR-TB. Given the lack of appropriate facilities in resource-limited settings, such patients are being discharged back into the community where there is likely ongoing disease spread. In the absence of effective drug regimens, in appropriate patients, surgery is a critical part of management. Here we review the diagnosis, medical and surgical management of MDR-TB and XDR-TB.

Indexed as

drug resistanceExtensively drug-resistant tuberculosis (XDR-TB)surgery

Identifiers

PMID24624282
PMCPMC3949182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.